United Nations Children's Fund (UNICEF), New York, USA.
John Snow Research and Training Institute, Inc., Yangon, Myanmar.
Glob Health Sci Pract. 2017 Jun 27;5(2):202-216. doi: 10.9745/GHSP-D-16-00312.
The World Health Organization recently provided guidelines for outpatient treatment of possible severe bacterial infections (PSBI) in young infants, when referral to hospital is not feasible. This study evaluated newborn infection treatment at the most peripheral level of the health system in rural Ethiopia.
We performed a cluster-randomized trial in 22 geographical clusters (11 allocated to intervention, 11 to control). In both arms, volunteers and government-employed Health Extension Workers (HEWs) conducted home visits to pregnant and newly delivered mothers; assessed newborns; and counseled caregivers on prevention of newborn illness, danger signs, and care seeking. Volunteers referred sick newborns to health posts for further assessment; HEWs referred newborns with PSBI signs to health centers. In the intervention arm only, between July 2011 and June 2013, HEWs treated newborns with PSBI with intramuscular gentamicin and oral amoxicillin for 7 days at health posts when referral to health centers was not possible or acceptable to caregivers. Intervention communities were informed of treatment availability at health posts to encourage care seeking. Masking was not feasible. The primary outcome was all-cause mortality of newborns 2-27 days after birth, measured by household survey data. Baseline data were collected between June 2008 and May 2009; endline data, between February 2013 and June 2013. We sought to detect a 33% mortality reduction. Analysis was by intention to treat. (ClinicalTrials.gov registry: NCT00743691).
Of 1,011 sick newborns presenting at intervention health posts, 576 (57%) were identified by HEWs as having at least 1 PSBI sign; 90% refused referral and were treated at the health post, with at least 79% completing the antibiotic regimen. Estimated treatment coverage at health posts was in the region of 50%. Post-day 1 neonatal mortality declined more in the intervention arm (17.9 deaths per 1,000 live births at baseline vs. 9.4 per 1,000 at endline) than the comparison arm (14.4 per 1,000 vs. 11.2 per 1,000, respectively). After adjusting for baseline mortality and region, the estimated post-day 1 mortality risk ratio was 0.83, but the result was not statistically significant (95% confidence interval, 0.55 to 1.24; =.33).
When referral to higher levels of care is not possible, HEWs can deliver outpatient antibiotic treatment of newborns with PSBI, but estimated treatment coverage in a rural Ethiopian setting was only around 50%. While our data suggest a mortality reduction consistent with that which might be expected at this level of coverage, they do not provide conclusive results.
世界卫生组织最近为无法转诊至医院的婴幼儿疑似严重细菌感染(PSBI)的门诊治疗提供了指导。本研究评估了埃塞俄比亚农村卫生系统最基层的新生儿感染治疗情况。
我们在 22 个地理区域(11 个分配至干预组,11 个分配至对照组)开展了一项整群随机试验。在两组中,志愿者和政府雇用的卫生推广工作者(HEW)均对孕妇和刚分娩的母亲进行家访;评估新生儿情况;并向照顾者提供关于预防新生儿疾病、危险信号和寻求医疗的咨询。志愿者将患病的新生儿转介至卫生所进行进一步评估;HEW 将出现 PSBI 体征的新生儿转介至卫生中心。仅在干预组中,自 2011 年 7 月至 2013 年 6 月,当转介至卫生中心不可行或不被照顾者接受时,HEW 用肌内注射庆大霉素和口服阿莫西林为有 PSBI 体征的新生儿治疗 7 天。干预社区被告知卫生所提供治疗,以鼓励寻求治疗。无法进行盲法。主要结局是出生后 2-27 天的新生儿全因死亡率,通过家庭调查数据进行测量。基线数据收集于 2008 年 6 月至 2009 年 5 月;终点数据收集于 2013 年 2 月至 2013 年 6 月。我们旨在检测死亡率降低 33%。分析为意向治疗。(临床试验.gov 注册号:NCT00743691)。
在干预卫生所就诊的 1011 名患病新生儿中,有 576 名(57%)被 HEW 确定至少有 1 项 PSBI 体征;90%拒绝转诊并在卫生所接受治疗,至少有 79%完成了抗生素疗程。卫生所的估计治疗覆盖率约为 50%。干预组第 1 天新生儿死亡率下降(从基线时每 1000 例活产中 17.9 例死亡降至第 1 天结束时每 1000 例活产中 9.4 例死亡),明显多于对照组(从每 1000 例活产中 14.4 例死亡降至每 1000 例活产中 11.2 例死亡)。调整基线死亡率和区域后,估计第 1 天的死亡风险比为 0.83,但结果无统计学意义(95%置信区间,0.55 至 1.24;=0.33)。
当无法转诊至更高一级的医疗机构时,HEW 可以为有 PSBI 的新生儿提供门诊抗生素治疗,但在埃塞俄比亚农村地区,估计的治疗覆盖率仅为 50%左右。虽然我们的数据提示死亡率降低与这一覆盖水平下可能出现的死亡率降低一致,但并不能提供确凿的结论。